Leanne Berry

2.4k citations

24 papers · 1.7k indexed · h-index 14

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
Cancer Research top 10%

Papers in ⓘ

Oncology 12
- HER2/EGFR in Cancer Research 5
- Cancer Cells and Metastasis 3
Hematology 3

Co-authors: Marcia Belvin (8 shared papers)Lori S. Friedman (9 shared papers)Mark R. Lackner (4 shared papers)Carol O’Brien (4 shared papers)Klaus P. Hoeflich (5 shared papers)Heidi Savage (3 shared papers)Lukas C. Amler (3 shared papers)Elizabeth A. Punnoose (2 shared papers)
Journals: Clinical Cancer Research (5 papers)Cancer Research (5 papers)Molecular Cancer Therapeutics (2 papers)American Journal of Otolaryngology (1 paper)Molecular Systems Biology (1 paper)
Partner nations: United States Germany France

In The Last Decade

Leanne Berry

22 papers receiving 1.6k citations

Peers

Countries citing papers authored by Leanne Berry

Since Specialization

Citations

This map shows the geographic impact of Leanne Berry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leanne Berry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leanne Berry more than expected).

Fields of papers citing papers by Leanne Berry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leanne Berry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leanne Berry. The network helps show where Leanne Berry may publish in the future.

Co-authors

The 25 scholars most cited alongside Leanne Berry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Leanne Berry Line = papers co-authored together Leanne Berry links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Clinical Cancer Research ·Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd, Guy Cavet, Steve Guerrero, Kenneth Jung, Tom Januario, Heidi Savage, Elizabeth A. Punnoose, Tom Truong, Wei Zhou, Leanne Berry, Lesley Murray, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner	2009	385
2	Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models Clinical Cancer Research ·Carol O’Brien, Jeffrey J. Wallin, Deepak Sampath, Debraj GuhaThakurta, Heidi Savage, Elizabeth A. Punnoose, Jane Guan, Leanne Berry, Wei Wei Prior, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner	2010	201
3	Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition Cancer Research ·Klaus P. Hoeflich, Mark Merchant, Christine Orr, Jocelyn Chan, Doug Den Otter, Leanne Berry, Ian Kasman, Hartmut Koeppen, Ken Rice, Nai-Ying Yang, Stefan Engst, Stuart H. Johnston, Lori S. Friedman, Marcia Belvin	2011	200
4	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression Cancer Research ·Klaus P. Hoeflich, Sylvia Herter, Janet Tien, Leo Lap-Yan Wong, Leanne Berry, Jocelyn Chan, Carol O’Brien, Zora Modrušan, Somasekar Seshagiri, Mark R. Lackner, Howard M. Stern, Edna F. Choo, Lesley Murray, Lori S. Friedman, Marcia Belvin	2009	144
5	Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers Cancer Cell ·Timothy R. Wilson, Diana Lee, Leanne Berry, David S. Shames, Jeff Settleman	2011	125
6	Network quantification of EGFR signaling unveils potential for targeted combination therapy Molecular Systems Biology ·Bertram Klinger, Anja Sieber, Raphaela Fritsche‐Guenther, Franziska Witzel, Leanne Berry, Dirk Schumacher, Yibing Yan, Pawel Durek, Mark Merchant, Reinhold Schäfer, Christine Sers, Nils Blüthgen	2013	119
7	Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy Clinical Cancer Research ·Anil Bagri, Leanne Berry, Bert Gunter, Mallika Singh, Ian Kasman, Lisa A. Damico, Hong Xiang, Maike Schmidt, Germaine Fuh, Beth Hollister, Oliver Rosen, Greg Plowman	2010	110
8	Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models Clinical Cancer Research ·Nguyen Tan, Mehnaz Malek, Jiping Zha, Yue Peng, Robert Kassees, Leanne Berry, Wayne J. Fairbrother, Deepak Sampath, Lisa D. Belmont	2011	83
9	GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo Clinical Cancer Research ·Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, Deepak Sampath	2012	73
10	Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Molecular Cancer Therapeutics ·Jiping Zha, Carol O’Brien, Heidi Savage, Ling‐Yuh Huw, Fiona Zhong, Leanne Berry, Gail D. Lewis Phillips, Elizabeth Luis, Guy Cavet, Xiaolan Hu, Lukas C. Amler, Mark R. Lackner	2009	66
11	Quantification of viable tumor microvascular characteristics by multispectral analysis Magnetic Resonance in Medicine ·Leanne Berry, Kai Barck, Mary Ann T. Go, Jed Ross, Xiumin Wu, Simon P. Williams, Alvin Gogineni, Mary J. Cole, Nicholas van Bruggen, Germaine Fuh, Frank Peale, N. Ferrara, Sarajane Ross, Ralph Schwall, Richard A.D. Carano	2008	40
12	The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma Oncogene ·Veerendra Munugalavadla, Sanjeev Mariathasan, Dionysos Slaga, Cheng Du, Leanne Berry, Geoff Del Rosario, Y. Yan, Marigold Boe, Ling Sun, Lori S. Friedman, Marta Chesi, P. Leif Bergsagel, Allen Ebens	2013	37
13	PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts Cancer Chemotherapy and Pharmacology ·Edna F. Choo, Chee M. Ng, Leanne Berry, Marcia Belvin, Nicholas Lewin‐Koh, Mark Merchant, Laurent Salphati	2012	26
14	Stromal cell involvement in leukemogenesis and carcinogenesis. PubMed ·Greenberger Js, Epperly Mw, Adriana Zeevi, Brunson Kw, Goltry Kl, Pogue-Geile Kl, Jenifer A. Bray, Leanne Berry	1996	21
15	Effect of anti-TGF-beta antibodies in syngeneic mouse models of metastasis. PubMed ·Richard A.D. Carano, Li Y, Ming Bao, Li J, Leanne Berry, Jed Ross, Jeanne Kowalski, Dorothy French, Debra L. Dugger, Ralph Schwall, Y Wang, Fei D, Moseley Sl, Filvaroff Eh	2004	7
16	515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel European Journal of Cancer Supplements ·Teemu T. Junttila, Carter T. Fields, G. Li, Lisa Crocker, Kathryn L. Parsons, Leanne Berry, Klára Tótpál, Gail D. Lewis Phillips, Mark X. Sliwkowski	2008	5
17	132 Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumor growth inhibition in vivo European Journal of Cancer Supplements ·Marcia Belvin, Leanne Berry, Julie Chan, Doug Den Otter, Lori S. Friedman, Klaus P. Hoeflich, Hartmut Koeppen, Mohammed Merchant, C. Orr, Kenner Rice	2010	4
18	Abstract 3295: Inhibiting vascular morphogenesis in tumors: EGFL7 as a novel therapeutic target Cancer Research ·Stacey Yeung, Tanya Smyczek, Jason Cheng, Anthony Lima, Rafael Molina, Patricia Hamilton, Jason E. Long, Leanne Berry, Michelle Nannini, Kai Barck, Hani Bou-Reslan, Tim C. Cao, Calvin Ho, Richard A.D. Carano, Ian Kasman, Greg Plowman, Mallika Singh, Weilan Ye, Leisa Johnson	2011	4
19	Mechanistic evaluation of the combination effect of anti-VEGF and chemotherapy Cancer Research ·Ian Kasman, Anil Bagri, Judy Mak, Franklin Peale, Rick Carano, Jed Ross, Leanne Berry, Young Cheol Shin, Patrick J. Rudewicz, Cary D. Austin, Ronald E. Ferrando, Sarajane Ross, Lisa Crocker, Nicolas Van Bruggen, Harriet Pais, Kurt Scudder, Beth Hollister, Greg Plowman	2008	3
20	116 (PB104): Preclinical characterization of SKY-1214, a small molecule splicing modulator of Fanconi Anemia pathway members for the treatment of multiple myeloma and non-Hodgkin’s lymphoma European Journal of Cancer ·Sebastian Rauch, S.O. Reber, M. Perez Salvia, Massimo Pregnolato, Botao Li, Leanne Berry, Olesia Buiakova, Hasane Ratni, Brian Gudenas, Carlo Cusulin, Lindsey Shanahan, Valerio Costa, Sergey Paushkin	2024	1

About Leanne Berry

Leanne Berry is a scholar working on Oncology, Hematology, Otorhinolaryngology, Molecular Biology and Periodontics, having authored 24 papers that have together received 1.7k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (6 papers), HER2/EGFR in Cancer Research (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Protein Degradation and Inhibitors (3 papers), Cancer Cells and Metastasis (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), Angiogenesis and VEGF in Cancer (3 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Oncology (715 citations), Cancer Research (267 citations), Molecular Biology (1.2k citations), Genetics (136 citations) and Pathology and Forensic Medicine (182 citations). Leanne Berry has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Marcia Belvin, Lori S. Friedman, Mark R. Lackner, Carol O’Brien, Klaus P. Hoeflich, Heidi Savage, Lukas C. Amler, Elizabeth A. Punnoose, Lesley Murray and Deepak Sampath. Their work appears in journals such as Clinical Cancer Research, Cancer Research, Molecular Cancer Therapeutics, American Journal of Otolaryngology and Molecular Systems Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact